CClinicalTrials.gg
Not yet recruitingNCT07808593Updated Sep 9, 2026

Artificial Intelligence - Based Opportunistic Coronary Artery Calcium Scoring on Routine Chest-CT Scan

An observational study in Coronary Artery Calcification, Cardiovascular Risk and Coronary Artery Disease, sponsored by University of Cologne. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by University of Cologne · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,950
Ages
18 Years and older
Sex
All
01

Study summary

This retrospective, non-interventional study externally validates a pre-trained open-weight deep-learning algorithm (Swin-UNETR) for the opportunistic quantification of coronary artery calcium (CAC) on non-gated routine chest CT scans acquired at a German academic center, and evaluates the prognostic value of this automated imaging biomarker for cardiovascular risk stratification. Coronary calcium is an established predictor of cardiovascular risk, but is not routinely quantified on the tens of thousands of non-cardiac chest CTs performed each year. Because existing high-performing AI models were trained almost exclusively on U.S. cohorts, external validation on a European scanner fleet is required to exclude scanner bias (domain shift). The study comprises three linked analytic cohorts: (1) a validation cohort comparing the AI-CAC score against the ECG-gated cardiac CT Agatston reference; (2) a dialysis cohort assessing calcification progression and mortality; and (3) an emergency department cohort assessing short-term cardiovascular events. This is an investigator-initiated trial with no intervention on patients.

Read the detailed description

The study analyzes a retrospective cohort of routine clinical CT examinations at University Hospital Cologne. Data originate from the hospital information system and Picture Archiving and Communication System (PACS) and are provided in pseudonymized form via the Medical Data Integration Center (MeDIC), acting as an independent trusted third party; the re-identification key remains under the sole control of MeDIC. Deep-learning inference is performed locally on isolated, access-controlled graphics processing unit (GPU) clusters of the institution (privacy by design / zero data retention); an open-weight model (Swin-UNETR) is used.

Three research questions are addressed in three analytic cohorts:

  • Validation (n ≈ 150): diagnostic agreement of the automatically extracted AI-CAC score (from the non-gated CT) with the reference Agatston score from a paired ECG-gated cardiac CT acquired within ≤ 12 months.
  • Dialysis (n ≈ 300): 150 hemodialysis patients plus 150 matched kidney-healthy controls with serial non-gated CTs; annualized calcification progression rate and all-cause mortality.
  • Emergency department (n ≈ 1,500): patients > 50 years with non-gated chest CTs from the Emergency Department (without a primary cardiac focus); occurrence of in-hospital major adverse cardiac event (MACE) or cardiovascular readmission within 12 months.

Extracted data include demographics (age at examination, sex), cardiovascular risk factors and comorbidities (ICD-10), long-term medication, laboratory values, examination metadata (date, scanner manufacturer, kilovolt peak (kVp), slice thickness), and outcome data (mortality, cardiovascular events, readmissions). Statistical analysis uses Spearman correlation, Cohen's kappa and Bland-Altman analysis for method comparison; t-test / Mann-Whitney-U for group differences in progression; and Kaplan-Meier (log-rank) plus multivariable Cox proportional-hazards and logistic regression for outcome prediction. Legal basis: § 6 (1) no. 2 Health Data Use Act of Germany (GDNG) in conjunction with Art. 9 (2) (j) and Art. 89 (1) GDPR (research privilege); no individual consent (disproportionate effort, Art. 14 (5) (b) GDPR). The AI (artificial intelligence) model carries no CE-marking and is used strictly as a research tool; AI-CAC scores are not systematically fed back into clinical care.

02

Conditions studied

  • Coronary Artery Calcification
  • Cardiovascular Risk
  • Coronary Artery Disease
  • End-Stage Renal Disease Requiring Haemodialysis
  • Emergency Care

Keywords

  • Coronary Artery Calcification
  • Coronary Artery Disease
  • Opportunistic Screening
  • Artificial Intelligence
  • Deep Learning
  • Chest CT
  • Agatston Score
  • External Validation
  • Cardiovascular Risk Stratification
  • Hemodialysis
  • MACE
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Retrospective patients at University Hospital Cologne with routine clinical CT imaging (01 January 2015 - 31 December 2025), across three analytic cohorts (validation, dialysis, emergency department); approximately 1,950 cases.

Inclusion criteria

  • Validation cohort: patients with a paired non-gated chest CT and an ECG-gated cardiac CT acquired within ≤ 12 months.
  • Dialysis cohort: hemodialysis patients with serial non-gated CTs, plus matched kidney-healthy controls.
  • Emergency department cohort: patients > 50 years with non-gated chest CTs from the Emergency Department without a primary cardiac focus.

Exclusion criteria

Exclusion Criteria:

  • Documented objection to the scientific use of the data pursuant to Art. 21 GDPR.
  • Cases lacking the minimum data required for analysis (insufficient image quality or missing reference/outcome data).
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,950 participants (estimated)
Patient registry
No

Groups and cohorts

  • Validation Cohort

    Paired non-gated chest CT and ECG-gated cardiac CT (≤ 12 months apart). AI-CAC score compared against the reference Agatston score. n ≈ 150.

  • Dialysis Cohort

    150 hemodialysis patients plus 150 matched kidney-healthy controls with serial non-gated CTs. Calcification progression and all-cause mortality. n ≈ 300.

  • Emergency Department Cohort

    Patients \> 50 years with non-gated chest CTs from the emergency department without primary cardiac focus. In-hospital MACE / cardiovascular readmission within 12 months. n ≈ 1,500

05

What researchers measure

Primary outcomes

  1. Diagnostic agreement of the AI-CAC score with the reference Agatston score

    Agreement between the automatically extracted AI-CAC score from the non-gated chest CT and the reference Agatston score from a paired ECG-gated cardiac CT, reported as Spearman correlation coefficient, Cohen's kappa across established risk classes (0, 1-100, 101-400, \> 400), and Bland-Altman limits of agreement; supplemented by sensitivity, specificity, positive predictive value(PPV)/negative predictive value(NPV) and F1 score

    Time frame: At the index non-contrast chest CT (Day 0) and at the paired ECG-gated cardiac CT obtained within 12 months after the index CT.

  2. Annualized calcification progression rate and all-cause mortality

    Difference in the mean annual increase in AI-CAC between hemodialysis patients (dialysis cohort) and matched kidney-healthy controls measured on serial non-gated CTs (t-test / Mann-Whitney-U), and all-cause mortality analyzed by Kaplan-Meier (log-rank) and multivariable Cox proportional-hazards models (hazard ratios adjusted for confounders

    Time frame: From the index non-contrast chest CT (Day 0) through the last available serial non-gated chest CT and the end of individual follow-up, up to 10 years per participant.

  3. In-hospital Major Adverse Cardiac Event or cardiovascular readmission within 12 months (Emergency Department cohort).

    Occurrence of in-hospital Major Adverse Cardiovascular Events (myocardial infarction, stroke, resuscitation) or cardiovascular readmission within 12 months of the index Emergency Department visit, in relation to an unrecognized high AI calcium score (\> 400); reported as adjusted odds ratios and hazard ratios from logistic regression and Cox models

    Time frame: 12 months after the index emergency department visit

Secondary outcomes

  1. Technical feasibility and inference time of the open-source AI model on local GPU clusters

    Inference time per case and technical feasibility of running the open-weight deep-learning model (Swin-UNETR) as an isolated container on the institution's local GPU infrastructure

    Time frame: At the index non-contrast chest CT (Day 0)

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07808593
Lead sponsor
University of Cologne
Collaborators
Institute for Diagnostic and Interventional Radiology, University Hospital Cologne, Medical Data Integration Center (MeDIC), University Hospital Cologne
Responsible party
Volker Burst (Prof. Dr., University of Cologne) — Principal investigator
First posted
Sep 9, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Cem Özel, MD
Contact
cem.oezel@uk-koeln.de
+49 176 2113 7580
Carsten Gietzen, MD
Contact
carsten.gietzen@uk-koeln.de
Cem Özel, MD
principal investigator · Department of Internal Medicine II, University Hospital Cologne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion